



Ifw

Express Mail No.: EV452774832US

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Zeldis

Confirmation No.: 1866

Application No.: 10/699,110

Group Art Unit: 1614

Filed: October 30, 2003

Examiner: To Be Assigned

For: METHODS OF USING AND
COMPOSITIONS COMPRISING
SELECTIVE CYTOKINE
INHIBITORY DRUGS FOR
TREATMENT AND
MANAGEMENT OF MACULAR
DEGENERATION

Attorney Docket No.: 9516-083-999

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. §1.56 AND §1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to references **A82** to **A86** listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant."

Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing reference and that the reference be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), Applicants estimate that no fee is due in connection with the filing of this Information Disclosure Statement. However, should the Patent Office determine otherwise, please charge the necessary fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: March 25, 2005

by Yeahsil Moon Reg No 52, 042
Anthony M. Insogna 35,203
(Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017-6702
(212) 326-3939

Enclosures

(Use several sheets if necessary)

1614

[illegible][illegible]

/ZF/	A84	Bressler, 1999, "Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP Report 1," Archives of Ophthalmol. 117(10):1329-1345
/ZF/	A85	Hunt, 2002, Rostapofrin (Miravant Medical Technologies) IDrugs 5(2):180-186
/ZF/	A86	Ohno-Matsui et al., 2001, "Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors FEGF and PEDF," J. Cell. Physiol. 189(3):323-333

DATE CONSIDERED

NYJD: 1564345.1